MaxCyte outlines $30M–$32M 2026 revenue target as ExPERT DTx launch and SPL milestones drive outlook (NASDAQ:MXCT)


Follow us on Google for the latest stock news

Earnings Call Insights: MaxCyte (MXCT) Q4 2025

Management View

  • Maher Masoud, President, CEO & Executive Director, highlighted that 2025 was a challenging year but also one of “meaningful progress for MaxCyte.” The company acquired SeQure DX, integrated the business, and launched the ExPERT DTx platform. Masoud stated, “We made meaningful changes

Seeking Alpha’s Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.



Source link

E.T.'s Henry Thomas Gives Rare Interview on Child Stardom Difficulties

‘NCIS’ Shocker As Veteran Cast Member Exits In Series’ 500th Episode

Leave a Reply

Your email address will not be published. Required fields are marked *